Related Experiment Video
Updated: Jul 19, 2026
06:21
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Psychotropic medications and leukopenia.
1Drexel University College of Medicine, Philadelphia, PA, USA.
Current Drug Targets
|October 5, 2006
Summary
Certain psychotropic drugs, like clozapine and carbamazepine, can cause neutropenia and agranulocytosis, requiring careful blood cell monitoring. Management involves drug adjustment, discontinuation, or treatments like filgrastim, depending on the cause.
Area of Science:
- Pharmacology
- Hematology
- Psychiatry
Background:
- Neutropenia and agranulocytosis are serious side effects of some psychotropic medications.
- Clozapine and carbamazepine are associated with the highest incidence of these blood disorders.
- Bone marrow suppression can stem from allergic reactions or direct toxicity.
Purpose of the Study:
- To review the incidence and management of drug-induced neutropenia and agranulocytosis.
- To highlight the importance of blood cell monitoring for patients on specific psychotropic drugs.
- To discuss various treatment strategies for managing these hematological adverse effects.
Main Methods:
- Literature review of psychotropic drug-induced hematological side effects.
- Analysis of incidence rates for neutropenia and agranulocytosis.
- Summary of management and treatment options.
Main Results:
- Clozapine and carbamazepine necessitate long-term blood cell monitoring due to high incidence of neutropenia/agranulocytosis.
- Drug-induced bone marrow suppression etiology dictates management: discontinuation for hypersensitivity (clozapine), dose adjustment for toxicity (carbamazepine).
- Treatment options include filgrastim, sargramostim, and lithium.
Conclusions:
- Continuous blood cell monitoring is crucial for patients on clozapine and advised for those on other psychotropics like carbamazepine.
- Understanding the mechanism of bone marrow suppression is key to effective patient management.
- Prompt intervention can mitigate the risks associated with these severe medication side effects.
Related Concept Videos
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications